title: [Hypomethylating agents for the treatment of myelodysplastic syndromes].
abstract: Azacitidine has been approved in January 2009 in Europe in the treatment of higher-risk myelodysplastic syndromes (MDS). This represents the first time a drug is specifically labelled in MDS in Europe, and is a cornerstone in the development of hypomethylating agents 5-azacytidine (azacitidine) and 5-deoxyazacytidine (decitabine). Clinical trials of hypomethylating agents in MDS still raise a number of questions regarding the precise mode of action of these drugs, as well as the optimal sequencing of treatment in MDS. The positive results of these trials also open the field of epigenetic therapeutic strategies combining hypomethylating agents with other classes of drugs targeting epigenetic processes.
authors.affiliation: Institut Gustave-Roussy, Villejuif, France, Hôpital Avicenne, service d'hématologie clinique, Bobigny, France.
authors.forename: Raphael
authors.initials: R
authors.lastname: Itzykson
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D019175:DNA Methylation / Q000187:drug effects; D000077209:Decitabine; D044127:Epigenesis, Genetic / Q000235:genetics; D006801:Humans; D009154:Mutation / Q000235:genetics; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000964:Antimetabolites, Antineoplastic; D000077209:Decitabine; D001374:Azacitidine